Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,018 across all filing types
Latest filing 2017-07-21 Earnings Release
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
Bimekizumab Phase 2b results FR
Earnings Release Classification · 95% confidence The document is a press release dated July 21, 2017, announcing positive results from the Phase 2b clinical study (BE ABLE) for the drug bimekizumab in treating psoriasis. It details efficacy endpoints (PASI90), safety profiles, and future development plans (Phase 3). The text explicitly states, 'UCB a annoncé aujourd'hui des résultats positifs pour BE ABLE...' and 'UCB prévoit de présenter et publier les résultats complets de BE ABLE début 2018.' This structure—announcing clinical trial results and future publication plans—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses on the initial release of key clinical trial results rather than being a comprehensive periodic financial report (10-K or IR), and it is not a transcript (CT) or a formal investor presentation (IP), the most fitting category is Earnings Release (ER), as these announcements often contain the most material, recent operational/clinical news. Alternatively, because it is a specific announcement about clinical trial data, it could be considered a Regulatory Filing (RNS) if ER is too broad, but ER is better suited for the release of key performance indicators (even clinical ones) that impact investor outlook. Given the focus on 'résultats positifs' and the immediate communication of data, ER is the primary fit, although it is not a standard quarterly financial earnings report. Q3 2017
2017-07-21 French
Bimekizumab Phase 2b results NL
Earnings Release Classification · 98% confidence The document is a press release dated July 21, 2017, announcing positive topline results from the Phase 2b BE ABLE clinical trial for the drug bimekizumab in treating psoriasis. It details efficacy data (PASI90 results), safety profiles, and future development plans (Phase 3). The text explicitly states it is 'gereguleerde informatie' (regulated information) and contains detailed scientific and clinical trial information, which is characteristic of an Earnings Release (ER) or a specific announcement related to clinical trial outcomes. Since it is an initial announcement of results (topliner results) rather than a comprehensive periodic report (like 10-K or IR), and it focuses on financial/operational performance highlights (clinical trial success), the most appropriate classification is Earnings Release (ER). It is not a full transcript (CT), a formal annual report (10-K), or a general regulatory filing (RNS), as it is a specific, high-value announcement. Q3 2017
2017-07-21 Dutch
20170608 - Transparency notification BlackRock Inc.pdf
Major Shareholding Notification Classification · 99% confidence The document is a 'Transparency notification' from UCB SA/NV announcing that BlackRock, Inc. has crossed the 3% threshold of voting rights following an acquisition of shares. This type of filing, which reports changes in significant share ownership levels by an entity, directly corresponds to the definition of Major Shareholding Notification (MRQ). The text explicitly details the previous holding, the new holding, the date the threshold was crossed, and the total number of shares, which are hallmarks of a major shareholding disclosure.
2017-06-08 English
20170608 - Notification de transparence BlackRock Inc.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de transparence BlackRock, Inc." and explicitly states that UCB SA is announcing receipt of a transparency declaration from BlackRock, Inc. The content details the acquisition of voting shares by BlackRock, causing their holding to cross the 3% threshold on June 1, 2017, as required by Belgian law (Article 14 of the law of May 2, 2007). This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category. It is not an Earnings Release (ER), Annual Report (10-K), or Interim Report (IR) as it focuses solely on ownership changes, not comprehensive financial performance. It is a specific regulatory disclosure regarding insider/major holdings.
2017-06-08 French
20170608 - Transparantieverklaring BlackRock Inc.pdf
Major Shareholding Notification Classification · 98% confidence The document is a 'Transparantieverklaring' (Transparency Declaration) issued by UCB NV, announcing that BlackRock, Inc. has crossed the 3% threshold of voting rights due to an acquisition of shares, effective June 1, 2017. This type of mandatory disclosure regarding changes in significant share ownership (crossing thresholds) directly corresponds to the definition of Major Shareholding Notification (MRQ). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific regulatory disclosure about ownership changes, making MRQ the most accurate classification.
2017-06-08 Dutch
20170602 - Transparency notifications BlackRock Inc 4TP.pdf
Major Shareholding Notification Classification · 98% confidence The document is a 'Transparency notification' from BlackRock, Inc. regarding changes in its shareholding in UCB SA/NV, specifically noting when the 3% threshold was crossed (both up and down) on various dates in May 2017. This type of filing, which reports personal share transactions by executives or major shareholders crossing regulatory thresholds, directly corresponds to the definition of Director's Dealing (DIRS) or Major Shareholding Notification (MRQ). Since the document explicitly details the crossing of a major shareholding threshold (3%) and lists the resulting share counts and percentages for various affiliated entities of BlackRock, it is best classified as a Major Shareholding Notification (MRQ). It is not an Earnings Release (ER), Annual Report (10-K), or a general Regulatory Filing (RNS), as MRQ is a more specific category for this content.
2017-06-02 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.